Biomea Fusion, Inc. · NASDAQ:BMEA
Biomea Fusion — Technical Presentation (October 2024)
26 slides from Biomea Fusion's technical presentation, Oct 31, 2024
Slide 1: Biomea Conference Call: Preclinical Data Combining icovamenib with a GLP-1-Based Therapy & BMF-650
BIOMEA cONFERENCE Call Preclinical Data Combining icovamenib with a GLP-1-Based Therapy & Biomea’s Oral GLP-1 RA Candidate BMF-650 October 30, 2024 Exhibit 99.1
Slide 2: Legal Disclaimer & Forward-Looking Statements
Legal Disclaimer & Forward-Looking Statements Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future business and financial performance of Biomea Fusion, Inc. (the “Company”) and involve know
Slide 3: Agenda
Agenda Page Biomea Conference Call Slides 30 October 2024 - Presentation of GLP-1 RA Candidate (BMF-650) and Preclinical Combination Data with icovamenib Ramses Erdtmann Chief Operating Officer & Co-Founder of Biomea Thomas Butler Chief Executive Officer, Chairman of the Board & Co-Founder of Biomea
Slide 4: Type 2 Diabetes Progression is Driven by Loss of Beta Cell Mass
*Int. J. Mol. Sci. 2016, 17, 744; doi:10.3390/ijms17050744 Type 1 and type 2 diabetes both result in beta cell loss and reduction in beta cell mass. Current diabetes therapies are generally not observed to address the decrease in beta cell mass and beta cell health. Normal glucose tolerance (NGT) fo
Slide 5: Longer Dosing and Higher Dose Concentration Resulted in Greater Proportion of Proliferating Human Islet Beta Cells
Longer Dosing and Higher Dose Concentration Resulted in Greater Proportion of Proliferating Human Islet Beta Cells Proliferating beta cells plotted as fraction of total beta cells Biomea Conference Call Slides 30 October 2024 - Presentation of GLP-1 RA Candidate (BMF-650) and Preclinical Combination
Slide 6: Application of Advanced Confocal Microscopy to Study the Impact of Therapeutics on Human Beta Cell Health and Function
Application of Advanced Confocal Microscopy to Study the Impact of Therapeutics on Human Beta Cell Health and Function Biomea Conference Call Slides 30 October 2024 - Presentation of GLP-1 RA Candidate (BMF-650) and Preclinical Combination Data with icovamenib An optical cross-section through an int
Slide 7: Icovamenib (BMF-219) in Combination with a GLP-1 Based Therapy – An Overview of Pre-Clinical Findings
Icovamenib (BMF-219) in Combination with a GLP-1 Based Therapy – An Overview of Pre-Clinical Findings
Slide 8: Menin Suppresses GLP-1 Receptor Transcript Levels
Biomea Conference Call Slides 30 October 2024 - Presentation of GLP-1 RA Candidate (BMF-650) and Preclinical Combination Data with icovamenib Menin Suppresses GLP-1 Receptor Transcript Levels
Slide 9: Icovamenib Enhanced Responsiveness of Islets to GLP-1/GIP Dual Receptor Agonist - Tirzepatide
Cadaver derived human islets Combination Treatment: icovamenib Enhanced Responsiveness of Islets to GLP-1/GIP Dual Receptor Agonist - Tirzepatide Biomea Conference Call Slides 30 October 2024 - Presentation of GLP-1 RA Candidate (BMF-650) and Preclinical Combination Data with icovamenib Day 1 Perfor
Slide 10: Icovamenib Enhanced Responsiveness of Islets to GLP-1 Receptor Agonist - Semaglutide
Combination Treatment: icovamenib Enhanced Responsiveness of Islets to GLP-1 Receptor Agonist - Semaglutide Biomea Conference Call Slides 30 October 2024 - Presentation of GLP-1 RA Candidate (BMF-650) and Preclinical Combination Data with icovamenib Day 1 Perform GSIS -/+ Semaglutide (200nM) Culture
Slide 11: Icovamenib Enhanced Responsiveness of Islets to Small Molecule GLP-1 Receptor Agonists - Orforglipron and BMF-650
Combination Treatment: icovamenib Enhanced Responsiveness of Islets to Small Molecule GLP-1 Receptor Agonists - Orforglipron and BMF-650 Biomea Conference Call Slides 30 October 2024 - Presentation of GLP-1 RA Candidate (BMF-650) and Preclinical Combination Data with icovamenib
Slide 12: Combining Covalent Binding Menin Inhibitor icovamenib with GLP-1 Based Therapy
Potential benefits of using icovamenib together with approved GLP-1 based therapeutics: Lower dosing requirements of existing GLP-1 based therapy Improved tolerability Improved adherence Improved therapeutic window Improved initial responsiveness - Greater patient persistence and treatment results w
Slide 13: BMF-650 – An Investigational, Next-Generation, Oral Small Molecule GLP-1 Receptor Agonist
BMF-650 – An Investigational, Next-Generation, Oral Small Molecule GLP-1 Receptor Agonist
Slide 14: Drive for a Greater Therapeutic Window with Next-Generation GLP-1 Receptor Agonist BMF-650
Attributes of Biomea’s GLP-1 Receptor Agonist Development Candidate: Less PK variability Greater bioavailability Greater protein binding Less side effects Why a greater “Therapeutic Window”? Only 3 of 10 patients in the real-world setting are staying on a GLP-1 based therapy after 12 months Drive fo
Slide 15: BMF-650 Showed Favorable In Vitro On-Target Activity and Off-Target Selectivity
GLP-1 human EC50 b-arrestin1 EC50 b-arrestin2 EC50 BMF-650 < 5 nM > 10 mM > 10 mM orforglipron < 5 nM > 10 mM > 10 mM Good potency on-target No off-target concerns from counter-screening assays BMF-650 Showed Favorable In Vitro On-Target Activity and Off-Target Selectivity Biomea Conference Call Sli
Slide 16: BMF-650 Showed Improved Glucose-Stimulated Insulin Secretion in Ex Vivo Human Islets
BMF-650 demonstrated improved insulin secretion vs orforglipron BMF-650 Showed Improved Glucose-Stimulated Insulin Secretion in Ex Vivo Cultured Healthy Human Islet Experiment Biomea Conference Call Slides 30 October 2024 - Presentation of GLP-1 RA Candidate (BMF-650) and Preclinical Combination Dat
Slide 17: Pharmacokinetics of BMF-650 in Non-Human Primate and Rodent
Pharmacokinetics of BMF-650 Showed Very Good Non-Human Primate and Rodent Bioavailability with Low Inter-Individual Variability Biomea Conference Call Slides 30 October 2024 - Presentation of GLP-1 RA Candidate (BMF-650) and Preclinical Combination Data with icovamenib Compound cynomolgus PO T1/2 (h
Slide 18: Projected Human Dose for BMF-650 Similar Among the Oral Agents
Projected Human Dose for BMF-650 Similar Among the Oral Agents Dosages Used in Cynomolgus Monkeys are Species Dependent and Specific to Properties of Compounds Biomea Conference Call Slides 30 October 2024 - Presentation of GLP-1 RA Candidate (BMF-650) and Preclinical Combination Data with icovameni
Slide 19: Set up of Intravenous Glucose Tolerance Test in Cynomolgus Monkeys
Period of Anesthesia of Cynomolgus Monkeys Compound: Bolus and continuous infusion to steady-state level Measure glucose and Insulin for 40 min Glucose IV Cynomolgus monkeys (n=4) were anesthetized. Compounds were administered via IV route. Glucose was infused. Blood Glucose and Insulin levels were
Slide 20: BMF-650 Potentiated Glucose-Stimulated Insulin Secretion in Cynomolgus Monkeys
Vehicle BMF-650 0.05mg/kg BMF-650 0.1 mg/kg orforglipron Low dose (lit)* orforglipron High dose (lit)* AUC Mean (N=4) 4021 22930 42262 20304 22922 Insulin improvement 0 470% 951% 405% 470% *PNAS November 24, 2020. vol. 117 no. 47 29959-29967 High and low dosing levels for orforglipron based on publi
Slide 21: BMF-650 Potentiated Blood Glucose Reduction in Cynomolgus Monkeys
Vehicle BMF-650 0.05mg/kg BMF-650 0.1mg/kg orforglipron Low dose (lit)* orforglipron high dose (lit)* AUC Mean (N=4) 533 401 404 461 418 Glucose lowering 0 -25% -24% -14% -22% *PNAS November 24, 2020. vol. 117 no. 47 29959-29967 High and low dosing levels for orforglipron based on publications: 0.00
Slide 22: Set up of Appetite Suppression Test in Cynomolgus Monkeys
24 hours period PO 3 hours 90 min Rest of day No food Food Fasted monkeys (n=4) were dosed orally (PO) with compound. Food was presented starting at 3 hours post dose. Recorded food intake for time window 3 hours to 4.5 hours and the whole day. Design of study as multiday of active drug and multiday
Slide 23: BMF-650 Appetite Suppression in Cynomolgus Monkeys
Biomea Conference Call Slides 30 October 2024 - Presentation of GLP-1 RA Candidate (BMF-650) and Preclinical Combination Data with iovamenib Food consumption tested daily in cynomolgus monkeys (n=4) BMF-650 demonstrated good appetite suppression over 6 days BMF-650 Appetite Suppression in Cynomolgus
Slide 24: BMF-650 Appetite Suppression Compares Well to Orforglipron
High / low dose level for orforglipron from PNAS Nov 2020 Chugai/Lilly publication: 0.1 / 0.05 mg/kg Biomea Conference Call Slides 30 October 2024 - Presentation of GLP-1 RA Candidate (BMF-650) and Preclinical Combination Data with icovamenib Food consumption tested daily in cynomolgus monkeys (n=4)
Slide 25: Projected Timeline for BMF-650 with IND Filing Anticipated in 2H 2025
Program was placed on a timeline targeting IND submission in 2H 2025 Development plan for obesity and type 2 diabetes 1H 2025 2H 2025 IND-Filing GLP TOX-start Projected Timeline for BMF-650 with IND Filing Anticipated in 2H 2025 Biomea Conference Call Slides 30 October 2024 - Presentation of GLP-1 R
Slide 26: Thank You
THANK YOU Biomea Fusion 900 Middlefield Road, 4th floor Redwood City, CA, 94063 biomeafusion.com
Biomea Fusion — Technical Presentation (October 2024) on 6ix